24
Participants
Start Date
February 16, 2018
Primary Completion Date
April 5, 2018
Study Completion Date
April 15, 2018
EPA + DHA in SMEDS Formulation
A single dose of 500 mg EPA + DHA administered in a self-micro-emulsifying delivery system (SMEDS) formulation
Lovaza (active comparator; already FDA approved)
A single dose of 840 mg EPA + DHA administered as Lovaza. This intervention was used as an active comparator in this study. Lovaza was already FDA-approved when the study was conducted.
MB Clinical Research, LLC, Boca Raton
Great Lakes Clinical Trials, Chicago
Collaborators (1)
Pharmavite LLC
INDUSTRY
Midwest Center for Metabolic and Cardiovascular Research
OTHER